Core Viewpoint - The company has approved the use of idle raised funds and self-owned funds for cash management and entrusted financial management, ensuring the safety of funds and normal project construction [2][4]. Group 1: Cash Management Approval - The company plans to use up to RMB 100 million of idle raised funds and up to RMB 150 million of idle self-owned funds for cash management and entrusted financial management [2]. - The cash management products will be short-term investments with high safety and liquidity, with a maturity not exceeding 12 months [2]. Group 2: Redemption of Cash Management Products - The company has redeemed all principal and earnings from the cash management products as of the announcement date [3]. Group 3: Approval Process - The proposal for cash management was approved by the company's eighth board of directors and the eighth supervisory board meetings [4]. Group 4: Financial Impact - As of the announcement date, the company has a remaining balance of RMB 57 million in idle raised funds for cash management, which is within the authorized limit [9]. - The total remaining balance of self-owned funds used for cash management and entrusted financial management is RMB 114.0084 million, also within the authorized limit [9].

证券代码：301130 证券简称：西点药业 公告编号：2025-074 吉林省西点药业科技发展股份有限公司 关于使用闲置募集资金进行现金管理到期赎回的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于 2025 年 1 月 20 日召开第八届董事会第十次会议、第八届监事会第十次会议，分别审议通 过了《关于使用部分闲置募集资金进行现金管理及使用部分闲置自有资金进行现 金管理和委托理财的议案》，同意公司在确保募集资金投资项目建设正常进行和 资金安全的前提下，使用额度不超过人民币 1.0 亿元的部分闲置募集资金（含超 募资金）进行现金管理，公司及全资子公司在确保不影响公司日常经营的前提下， 使用额度不超过人民币 1.5 亿元的部分闲置自有资金进行现金管理和委托理财， 用于购买安全性高、流动性好、期限不超过 12 个月的短期投资理财产品。使用 期限自董事会审议通过之日起 12 个月内有效。在上述额度和期限内，资金可循 环滚动使用。具体内容详见公司在巨潮资讯网上披露的《关于使用部分闲置募集 资金进行现金管理及使 ...

Core Viewpoint - Zhonglun New Materials has launched its new energy film project in Xiamen, introducing the "Long Plastic High-Performance Capacitor Film," marking a significant advancement in China's high-end BOPP capacitor film sector [1] Company Summary - Zhonglun New Materials is recognized as a national manufacturing champion, expanding into the high-end BOPP capacitor film market with leading global technology [1] - The company is the only domestic entity capable of stable mass production of BOPP capacitor films with "large width, step line, and ultra-thin thickness below 3 microns" [1] - The newly launched production line features a 6.4-meter wide production line utilizing an innovative biaxial stretching process [1] Industry Summary - The "Long Plastic High-Performance Capacitor Film" is the only product in the industry that offers "zero joints, high performance, and zero defects," catering to the needs of the new energy vehicle and photovoltaic sectors [1] - This project, with a total investment of 2.5 billion yuan and covering an area of 134,400 square meters, aims to fill the domestic capacity gap in high-end capacitor films [1] - The initiative supports China's goal of reducing reliance on imports of high-end capacitor films, transitioning Zhonglun from the largest global BOPA film supplier to a comprehensive champion covering various high-performance film materials [1]

证券代码：301130 证券简称：西点药业 公告编号：2025-073 吉林省西点药业科技发展股份有限公司 三、审批程序 关于使用闲置募集资金及自有资金进行现金管理和委托理财 到期赎回并继续使用闲置募集资金进行现金管理的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于 2025 年 1 月 20 日召开第八届董事会第十次会议、第八届监事会第十次会议，分别审议通 过了《关于使用部分闲置募集资金进行现金管理及使用部分闲置自有资金进行现 金管理和委托理财的议案》，同意公司在确保募集资金投资项目建设正常进行和 资金安全的前提下，使用额度不超过人民币 1.0 亿元的部分闲置募集资金（含超 募资金）进行现金管理，公司及全资子公司在确保不影响公司日常经营的前提下， 使用额度不超过人民币 1.5 亿元的部分闲置自有资金进行现金管理和委托理财， 用于购买安全性高、流动性好、期限不超过 12 个月的短期投资理财产品。使用 期限自董事会审议通过之日起 12 个月内有效。在上述额度和期限内，资金可循 环滚动使用。具体内容详 ...

Core Viewpoint - The announcement details the progress of share reduction by major shareholders of Jilin Xidian Pharmaceutical Technology Development Co., Ltd., indicating that the reduction will not affect the company's control structure or governance [3][5][20]. Summary by Sections Shareholder Reduction Details - The main entities involved in the share reduction are Hengqin Dingdian Equity Investment Fund Partnership (Limited Partnership) and its concerted actor Zhuhai Hengqin Runhuiyi Investment Partnership (Limited Partnership), who hold over 5% of the shares [3][4]. - The total shares to be reduced amount to a maximum of 2,294,700 shares, which is not more than 3% of the company's total share capital [4]. - As of November 3, 2025, a total of 765,019 shares have been reduced, representing 1.0001% of the total share capital [4][5]. Shareholding Structure - After the reduction, Hengqin Dingdian and Zhuhai Hengqin Runhuiyi collectively hold 7,649,396 shares, which is 9.9999% of the total share capital, still qualifying them as major shareholders [3][5]. - The shareholding percentage decreased from 11.0000% to 9.9999% following the reduction [5]. Impact on Company Governance - The reduction will not lead to any changes in the company's controlling shareholder or actual controller, nor will it significantly impact the company's governance structure or ongoing operations [3][20]. - The reduction process is compliant with pre-disclosure regulations and does not trigger a mandatory tender offer [7][8]. Future Plans - The shareholders may continue to reduce their holdings within the next 12 months, depending on their financial needs [16].

Core Viewpoint - West Point Pharmaceutical (301130.SZ) announced a share reduction plan involving the sale of 765,019 shares, representing 1.0001% of the company's total equity, by Hengqin Dingdian and its concerted action party, Zhuhai Hengqin Runhuiyi, through centralized bidding or block trading from October 27, 2025, to November 3, 2025 [1] Summary by Category - **Share Reduction Details** - The share reduction involves a total of 765,019 shares [1] - This amount constitutes 1.0001% of the company's total share capital [1] - The reduction plan is not yet fully executed [1]

公司于近日收到持股 5%以上股东横琴鼎典及其一致行动人珠海横琴润汇易 出具的《简式权益变动报告书》。 现将具体情况公告如下： 一、本次权益变动的基本情况 证券代码：301130 证券简称：西点药业 公告编号：2025-072 吉林省西点药业科技发展股份有限公司 关于持股 5%以上股东及其一致行动人减持股份进展 暨权益变动的提示性公告 持股 5%以上股东横琴鼎典股权投资基金合伙企业（有限合伙）及其一致行动 人珠海横琴润汇易投资合伙企业（有限合伙）保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ●本次权益变动主体为持有吉林省西点药业科技发展股份有限公司（以下 简称"西点药业"或"公司"）5%以上股份的股东横琴鼎典股权投资基金合伙 企业（有限合伙）（以下简称"横琴鼎典"）及其一致行动人珠海横琴润汇易 投资合伙企业（有限合伙）（以下简称"珠海横琴润汇易"）通过集中竞价、 大宗交易方式减持股份，不触及要约收购； ● 本次权益变动后，横琴鼎典及其一致行动人珠海横琴润汇易合计持有公 司 7,649,396 ...

吉林省西点药业科技发展股份有限公司 简式权益变动报告书 上市公司名称：吉林省西点药业科技发展股份有限公司 信息披露义务人一：横琴鼎典股权投资基金合伙企业（有限合伙） 住所：珠海市横琴新区汇通三路 108 号办公 1114 信息披露义务人二：珠海横琴润汇易投资合伙企业（有限合伙） 住所：珠海市横琴琴朗道 151 号 1915 办公 股份变动性质：减少 签署日期：2025 年 11 月 3 日 - 1 - 股票上市地点：深圳证券交易所 公司股票简称：西点药业 公司股票代码：301130 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称《证券 法》）《上市公司收购管理办法》（以下简称《收购办法》）《公开发行证 券的公司信息披露内容与格式准则第 15 号—权益变动报告书》（以下简称《准 则第 15 号》）及相关的法律、法规和规范性文件编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《证券法》《收购办法》《准则第 15 号》的规定，本报告书已 全面披露信息义务人在吉林省西点药业科技发展股份有限公司（以下简称上 市公司或西点药业）拥有权益的股份变动情况。 截至本 ...

Company Overview and Development History - Xidian Pharmaceutical, founded in 1990, transitioned from a small drug trading company to the largest in Jilin Province by 1994 [2][3] - The company went public on the Shenzhen Stock Exchange's Growth Enterprise Market in 2022, with a reported revenue of CNY 256 million in 2024 [2][4] Key Milestones - Significant milestones include the establishment of Xidian Pharmaceutical in 2001, the launch of the "Ruixiangsu" project, and the company's listing in 2022 [3][4] - The company has focused on the research and development of "Ruixiangsu," a key product derived from the Longbai Ruixiang plant, leading to major breakthroughs in synthesis technology [3][4] Market Positioning and Strategy - Xidian Pharmaceutical positions itself in niche markets, focusing on chronic diseases prevalent among the elderly, with a strategy of "one core and two wings" [4][5] - The core product is "Ruixiangsu" capsules, complemented by unique products like "Fufang Tianshu Yao" and "Risperidone" [5][6] Performance and Growth Drivers - In 2024, the company reported a 13.71% increase in revenue, but a decline in net profit due to reduced government subsidies and rising raw material costs [6][7] - The increase in operating costs by CNY 15.69 million in 2024 was primarily due to the surge in traditional Chinese medicine prices [6][7] Future Profit Growth Drivers - Core product expansion and new indications for "Ruixiangsu" are expected to drive future profits [7][8] - The company plans to enhance its product pipeline through increased R&D investment, which rose by 17.52% in 2024 [8][11] Core Products and R&D Innovation - "Yiyuan Sheng" (Fufang Tianshu Yao) generated approximately CNY 112 million in revenue in 2024, accounting for 43.64% of total revenue [9][10] - "Risperidone" saw a significant revenue increase of 38.93%, contributing 40.62% to total revenue [10][11] R&D Focus and Strategy - The company emphasizes innovation through a dual strategy of "independent R&D and joint development," focusing on chronic diseases and blood-related conditions [11][12] - Ongoing research includes expanding the indications for "Ruixiangsu" to include conditions like diabetic complications and viral pneumonia [12][13] Future Strategic Planning - Xidian Pharmaceutical aims to deepen its existing market presence while selectively expanding into new therapeutic areas related to aging [14][15] - The company is transitioning to a dual-driven sales model, combining hospital and retail markets, and enhancing digital marketing efforts [16][17] Investor Relations and Market Concerns - The management views the current product structure as a competitive strength rather than a risk, with plans for diversification and product upgrades [17][18] - A cash dividend of CNY 2.6 per 10 shares is proposed, representing 49.39% of the net profit for 2024 [18][19] Market Valuation and Core Value - The company emphasizes its unique product advantages and strategic positioning in the aging population's healthcare needs [19][20] - Xidian Pharmaceutical holds 29 formulation varieties and 17 raw material drug registrations, establishing a solid foundation for future growth [20]

Core Insights - West Point Pharmaceuticals (301130.SZ) released its Q3 2025 report on October 28, 2025, indicating a total of 8 institutional investors holding shares, amounting to 18.83 million shares, which represents 24.62% of the total share capital [1] Institutional Holdings - The institutional investors include Dingdian Investment Management (Beijing) Co., Ltd., Zhuhai Hengqin Yanhe Health Technology Co., Ltd., and several others, with a total institutional holding percentage of 24.62% [1] - Compared to the previous quarter, the total institutional holding percentage decreased by 0.30 percentage points [1] Public Fund Holdings - One new public fund, Yimin Core Growth Mixed Fund, was disclosed this quarter, while 23 public funds were not disclosed compared to the previous quarter [1] - Notable funds that were not disclosed include Nuon An Multi-Strategy Mixed A, Everbright Baode Trust Quantitative Stock A, and others [1]